Journal of the Neurological Sciences
Volume 203 , Pages 41-48 , 15 November 2002

Relevant clinical outcomes in probable vascular dementia and Alzheimer's disease with cerebrovascular disease

  • John O'Brien

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44-191-256-3323; fax: +44-191-219-5051.
    • Institute for Ageing and Health, Newcastle General Hospital, Westgate Road, Newcastle-upon-Tyne NE4 6BE, UK
    • ,
  • Sean Lilienfeld

      Affiliations

    • Janssen Pharmaceutica, 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560, USA

References 

  1. Erkinjuntti T. Cerebrovascular dementia. Pathophysiology, diagnosis and treatment. CNS Drugs. 1999;12:35–48
  2. Erkinjuntti, T., Lilienfeld, S. Galantamine shows efficacy in patients with Alzheimer's disease with cerebrovascular disease or probable vascular dementia. Poster presented at the 53rd Annual Meeting of the American Academy of Neurology, Philadelphia PA, USA, May 2001.
  3. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement. Geriatr. Cogn. Disord. 1998;9(Suppl. 1):36–43
  4. Wilcock G, Stoeffer A, Sahin K, Moebius HJ. Neuro-radiological findings and the magnitude of cognitive benefit by memantine treatment. A subgroup analysis of two placebo-controlled clinical trials in vascular dementia. Eur. Neuropsychopharmacol. 2000;10(Suppl. 3):S360
  5. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S115–S123
  6. Maelicke A. The pharmacological rationale for treating vascular dementia with galantamine (Reminyl). Int. J. Clin. Pract. 2001;(Suppl. 120):24–28
  7. Róman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al.  Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250–260
  8. Rockwood K, Bowler J, Erkinjuntti T, Hachinski V, Wallin A. Subtypes of vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S59–S65
  9. Erkinjuntti T. Clinical deficits of Alzheimer's disease with cerebrovascular disease and probable VaD. Int. J. Clin. Pract. 2001;(Suppl. 120):14–23
  10. Kurz A. What is vascular dementia?. Int. J. Clin. Pract. 2001;(Suppl. 120):5–8
  11. Tatemichi TK, Desmond DW, Mayeux R, Paik M, Stern Y, Sano M, et al.  Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort. Neurology. 1992;42:1185–1193
  12. Desmond DW, Erkinjuntti T, Sano M, Cummings JL, Bowler JV, Pasquier F, et al.  The cognitive syndrome of vascular demential implications for clinical trials. Alzheimer Dis Assoc Disord. 1999;13(Suppl. 3):S21–S29
  13. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular cognitive impairment investigators of the Canadian study of health and aging. Neurology. 2000;54:447–451
  14. Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology. 1992;42:473–480
  15. Gold G, Giannakopoulos P, Montes-Paixao JC, Herrmann FR, Mulligan R, Michel JP, et al.  Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. Neurology. 1997;49:690–694
  16. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th ed.. Washington, DC: American Psychiatric Association; 2000;
  17. Rockwood K, MacKnight C, Wentzel C, Black S, Bouchard R, Gauthier S, et al.  The diagnosis of ‘mixed’ dementia in the Consortium for the Investigation of Vascular Impairment of Cognition (CIVIC). Ann. N.Y. Acad. Sci. 2000;903:522–528
  18. Gorelick PB, Nyenhuis DL, Garron DC, Cochran E. Is vascular dementia really Alzheimer's disease or mixed dementia?. Neuroepidemiology. 1996;15:286–290
  19. Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease [letter]. Lancet. 1999;354:919–920
  20. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbury WRI. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813–817
  21. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al.  Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 1997;11(Suppl. 2):S13–S21
  22. Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, et al.  A multicenter evaluation of new treatment efficacy instruments for Alzheimer's disease clinical trials: overview and general results. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 1997;11(Suppl. 2):S1–S12
  23. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am. J. Psychiatry. 1984;141:1356–1364
  24. Leber P. Guidelines for the clinical evaluation of anti-dementia drugs, 1st draft. Rockville, MD: US Food and Drug Administration; 1990;
  25. Committee for Proprietary Medicinal Products [CPMP]. Note for guidance on medicinal products in the treatment of Alzheimer's disease, 2002.
  26. Róman GC, Royall DR. Executive control function: a rational basis for the diagnosis of vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S69–S80
  27. Royall DR, Mahurin RK, Cornell J. Bedside assessment of frontal degeneration: distinguishing Alzheimer's disease from non-Alzheimer's cortical dementia. Exp. Aging Res. 1994;20:95–103
  28. Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: the executive interview. J. Am. Geriatr. Soc. 1992;40:1221–1226
  29. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189–198
  30. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study—clinical global impression of change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 1997;11(Suppl. 2):S22–S32
  31. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur. J. Neurol. 2000;7:159–169
  32. Guy W, Clinical Global Impressions [CGI]. In: Anon. ECDEU Assessment Manual for Psychopharmacology. US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976. p. 218–22.
  33. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br. J. Psychiatry. 1982;140:566–572
  34. Iwamoto T, Shimizu T, Ami M, Yoneda Y, Imamura T, Takasaki M. Dementia and disability after initial cerebral thrombosis evaluated by MRI and their clinical course. Nippon Ronen Igakkai Zasshi. 2000;37:162–169
  35. Gauthier S, Rockwood K, Gelinas I, Sykes L, Teunisse S, Orgogozo JM, et al.  Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S143–S147
  36. Marcusson J, Rother M, Kittner B, Rossner M, Smith RJ, Babic T, et al.  A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group. Dement. Geriatr. Cogn. Disord. 1997;8:320–328
  37. Lehfeld H, Reisberg B, Finkel S, Kanowski S, Wied V, Pittas J, et al.  Informant-rated activities-of-daily-living (ADL) assessments: results of a study of 141 items in the USA, Germany, Russia, and Greece from the International ADL Scale Development Project. Alzheimer Dis. Assoc. Disord. 1997;11(Suppl. 4):S39–S44
  38. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am. J. Occup. Ther. 1999;53:471–481
  39. Gauthier S, Ferris S. Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease. Int. J. Clin. Pract., Suppl. 2001;(Suppl. 120):29–39
  40. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al.  An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 1997;11(Suppl. 2):S33–S39
  41. Teunisse S, Derix MM, van Crevel H. Assessing the severity of dementia. Patient and caregiver. Arch. Neurol. 1991;48:274–277
  42. Patterson MB, Mack JL, Neundorfer MM, Martin RJ, Smyth KA, Whitehouse PJ. Assessment of functional ability in Alzheimer disease: a review and a preliminary report on the Cleveland scale for activities of daily living. Alzheimer Dis. Assoc. Disord. 1992;6:145–163
  43. Kunik ME, Huffman JC, Bharani N, Hillman SL, Molinari VA, Orengo CA. Behavioral disturbances in geropsychiatric inpatients across dementia types. J. Geriatr. Psychiatry Neurol. 2000;13:49–52
  44. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County study on memory in aging. Am. J. Psychiatry. 2000;157:708–714
  45. Vetter PH, Krauss S, Steiner O, Kropp P, Moller WD, Moises HW, et al.  Vascular dementia versus dementia of Alzheimer's type: do they have differential effects on caregivers' burden?. J. Geront. B Psychol. Sci. Soc. Sci. 1999;54:S93–S98
  46. Ballard C, Neill D, O'Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J. Affect. Disord. 2000;59:97–106
  47. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10–S16
  48. Aharon-Peretz J, Kilot D, Tomer R. Behavioural differences between white matter lacunar dementia and Alzheimer's disease: a comparison on the neuropsychiatric inventory. Dement. Geriatr. Cogn. Disord. 2000;11:294–298
  49. Reisberg B, Borenstein J, Salob SP, Ferris SH, Franssen E, Georgotas A. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J. Clin. Psychiatry, Suppl. 1987;48:9–15
  50. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J. Clin. Psychiatry. 1999;60:107–115
  51. Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal Bianco P, et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633–638
  52. DeKosky ST, Orgogozo JM. Alzheimer disease: diagnosis, costs, and dimensions of treatment. Alzheimer Dis. Assoc. Disord. 2001;15:S3–S7
  53. Hirono N, Kobayashi H, Mori E. Caregiver burden in dementia: evaluation with a Japanese version of the Zarit caregiver burden interview. No To Shinkei. 1998;50:561–567
  54. Zarit SH, Zarit JM. The memory behaviour and behaviour problems checklist and the burden interview. University Park, PA: Penn State Gerontology Center; 1990;
  55. Vitaliano PP, Russo J, Young HM, Becker J, Maiuro RD. The screen for caregiver burden. Gerontologist. 1991;31:76–83
  56. Winblad B, Wimo A, Almkvist O. Outcome measures in Alzheimer's disease: do they go far enough?. Dement. Geriatr. Cogn. Disord. 2000;11(Suppl. 1):3–10
  57. Vitaliano PP, Young HM, Russo J. Burden: a review of measures used among caregivers of individuals with dementia. Gerontologist. 1991;31:67–75
  58. Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T. Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences. Stroke. 2000;31:2952–2957
  59. Chui H, Gonthier R. Natural history of vascular dementia. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S124–S130
  60. Fischer P, Gatterer G, Marterer A, Simanyi M, Danielczyk W. Course characteristics in the differentiation of dementia of the Alzheimer type and multi-infarct dementia. Acta Psychiatr. Scand. 1990;81:551–553
  61. Ballard C, O'Brien J, Morris CM, Barber R, Swann A, Neill D, et al.  The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. Int. J. Geriatr. Psychiatry. 2001;16:499–503
  62. O'Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al.  Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology. 2001;56:1386–1388
  63. Kittner B. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis. Assoc. Disord. 1999;13(Suppl. 3):S166–S171
  64. Barclay LL, Zemcov A, Blass JP, Sansone J. Survival in Alzheimer's disease and vascular dementias. Neurology. 1985;35:834–840
  65. Martin DC, Miller JK, Kapoor W, Arena VC, Boller F. A controlled study of survival with dementia. Arch. Neurol. 1987;44:1122–1126
  66. McGonigal G, McQuade CA, Thomas BM, Whalley LJ. Survival in presenile Alzheimer's and multi-infarct dementias. Neuroepidemiology. 1992;11:121–126
  67. Aevarsson O, Svanborg A, Skoog I. Seven-year survival rate after age 85 years: relation to Alzheimer disease and vascular dementia. Arch. Neurol. 1998;55:1226–1232

PII: S0022-510X(02)00259-9

Journal of the Neurological Sciences
Volume 203 , Pages 41-48 , 15 November 2002

Article Tools

* Image Usage & Resolution